Managing multiple cardiovascular risk factors.

[1]  B. Davis,et al.  Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). , 2002, Journal of clinical hypertension.

[2]  J. Laragh,et al.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial , 2004, The Lancet.

[3]  David B Allison,et al.  Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. , 2004, Circulation.

[4]  B. V. Van Tassell,et al.  Medication nonadherence: an unrecognized cardiovascular risk factor. , 2007, MedGenMed : Medscape general medicine.

[5]  Oluf Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[6]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[7]  M Alan Brookhart,et al.  Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. , 2007, Archives of internal medicine.

[8]  S. Bangalore,et al.  Fixed-dose combinations improve medication compliance: a meta-analysis. , 2007, The American journal of medicine.

[9]  N. Clark,et al.  Standards of Medical Care in Diabetes: Response to Power , 2006 .

[10]  M. Laakso,et al.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.

[11]  R. Collins,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.

[12]  J. Laragh,et al.  VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk , 2003 .

[13]  S. Straus,et al.  Cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review , 2001, BMJ : British Medical Journal.

[14]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[15]  Seppo Lehto,et al.  Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. , 2005, Diabetes care.

[16]  D. Lau,et al.  overweight: updated meta-analysis Long term pharmacotherapy for obesity and , 2007 .

[17]  Thomas J. Bassler,et al.  Risk factors and coronary heart disease , 1976 .

[18]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[19]  M. Murphy,et al.  The effect of walking on fitness, fatness and resting blood pressure: a meta-analysis of randomised, controlled trials. , 2007, Preventive medicine.

[20]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[21]  B. Zinman,et al.  Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy , 2006, Diabetes Care.

[22]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[23]  M. Pfeffer,et al.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. , 2006, Circulation.